A First in Human Trial to Evaluate Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years https://www.medrxiv.org/content/10.1101/2022.12.27.22283128
A First in Human Trial to Evaluate Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years https://www.medrxiv.org/content/10.1101/2022.12.27.22283128